Loading company…
Superluminal Medicines uses AI, biology, and chemistry to discover drug candidates.
Superluminal Medicines is a Massachusetts, US-based drug development company founded in 2022 by Cony D'Cruz and Ajay Yekkirala. Its platform combines biology and chemistry expertise, machine learning, and data infrastructure to identify candidate compounds. In September 2026, it raised USD 60 million in Series B funding led by BVF Partners, with participation from Deep Track Capital, Eli Lilly and Company, Perceptive Advisors, Catalio Capital Management, Gaingels, GC&H Investments, Insight Partners, NVIDIA Corporation, and RA Capital Management. The funding was intended to support an obesity treatment trial, other drug programs, and platform development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in